DMK Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. The company is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Based on 9 analysts giving stock ratings to DMKPQ, updated on May 01, 2024
Strong Buy
Strong buy
3
Buy
5
Hold
1
Sell
0
Strong sell
0
Leveraging in-depth analyst evaluations, we have synthesized critical insights from expert assessments to deliver a robust outlook for DMKPQ. Our analysts highlight strong fundamentals and favorable market sentiment, positioning DMKPQ for significant upside potential in the near term. Based on this comprehensive expert analysis, we maintain a highly optimistic view of this stock. Our conclusion: DMKPQ is a Strong Buy candidate.
DMKPQ stock price ended at $0 on Thursday, after dropping NaN%
On the latest trading day Mar 26, 2026, the stock price of DMKPQ fell by NaN%, dropping from $NaN to $NaN. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $NaN and a high of $NaN. On the latest trading day, the trading volume for DMKPQ decreased by -- shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, -- shares were traded, with a market value of approximately --.
DMKPQ Technical Signals
Technical Signals Summary
Buy Signals 0
Neutral Signals 7
Sell Signals 0
Strong Sell
Sell
Neutral
Buy
Strong Buy
DMKPQ currently exhibits 0 buy signals and 0 sell signals. The stock has been in an downtrend since --, with a total price change of -- during this period. Overall, the technical indicators point to a Neutral outlook for the mid-term.
Bullish/Bearish Signals for DMKPQ
Our algorithms analyze key indicators like moving averages, RSI, MACD, and trading volume to generate bullish and bearish signals for DMKPQ. These insights help you make informed investment decisions.
Follow-Up Questions
How do technical analysis indicators apply to DMKPQ?
According to technical analysis, DMK Pharmaceuticals Corp has an aggregate signal of Neutral. DMK Pharmaceuticals Corp has 0 Buy signals, 7 Neutral Signals and 0 sell signals.
What is the RSI for DMK Pharmaceuticals Corp?
The RSI for DMK Pharmaceuticals Corp is currently 0, indicating a neutral condition
What is DMK Pharmaceuticals Corp price for the next 12 months?
DMK Pharmaceuticals Corp DMKPQ price for the next 12 months is estimated at $0.
How high is DMK Pharmaceuticals Corp expected to go?
According to wall street analysts, DMK Pharmaceuticals Corp is expected to reach a high forecast of $0.